Immutep Faces Securities Class Action Over TACTI-004 Trial Claims

The DJS Law Group filed the action citing violations of the Securities Exchange Act of 1934, specifically targeting statements made by the company during the lead-up to its January 30, 2026, SEC filing. While Immutep publicly characterized the TACTI-004 trial of its candidate drug, eftilagimod alfa, as showing strong operational progress, the complaint asserts that leadership was already aware the study would fail to meet its primary efficacy endpoints. Affected shareholders have until July 6, 2026, to seek appointment as lead plaintiff, though such a role is not a prerequisite for recovering potential losses. The firm, led by David J. Schwartz, is currently soliciting participants who suffered financial harm during the specified class period.